Amgen needs to start paying a dividend.
Amgen thinks that it is a scrappy little biotech. They sure are a biotech company, maybe even a little scrappy, but definitely not little. In fact, their growth numbers look anemic [they need a shot of EPO ]. Amgen was a duopoly for fifteen years – during this period, they sold two drugs – Epoetin ...